Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd (NQ: CYTO )

1.442 -0.008 (-0.57%)
Streaming Delayed Price Updated: 1:28 PM EDT, May 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Altamira Therapeutics Ltd

< Previous 1 2 3 4 Next >
Altamira Therapeutics Provides Update on Bentrio Program
- Building Bentrio™ brand and expanding in European markets - 510(k) premarket notification for allergy indication submitted to the U.S. Food and Drug Administration ("FDA") - Distributors signed up... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program
HAMILTON, BERMUDA / ACCESSWIRE / September 21, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
HAMILTON, BERMUDA / ACCESSWIRE / September 9, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results
- Commercial launch of Bentrio™ nasal spray in first EU markets, with plans to expand to additional European and international markets in the second half of 2021 - Enrollment in Phase 2 trial of AM-125... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Altamira Therapeutics Reports Protective Effects of Bentrio(TM) Nasal Spray Against Influenza A Virus (H1N1)
- Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection (p<0.01) - New data demonstrate protective effects in viral infections... 
From Altamira Therapeutics
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Exposures Death Intellectual Property Legal
Altamira Therapeutics Announces Launch of Website Dedicated to Bentrio(TM) Nasal Spray
HAMILTON, BERMUDA / ACCESSWIRE / August 3, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.